Supernus Pharmaceuticals Inc. Watch

from 8-K 1 page Supernus to Present at the 2019 Cantor Global Healthcare Conference

from 8-K 1 page Supernus to Present at Two September Healthcare Conferences

from 8-K 1 page Supernus Pharmaceuticals, Inc. Is a Pharmaceutical Company Focused on Developing and Commercializing Products for the Treatment of Central Nervous System (Cns) Diseases. the Company Currently Markets Trokendi Xr® (Extended-Release Topiramate) for the Prophylaxis of Migraine and the Treatment of Epilepsy, and Oxtellar Xr® (Extended-Release Oxcarbazepine) for the Treatment of Epilepsy. the Company Is Also Developing Several Product Candidates to Address Large Market Opportunities in the Cns Market, Including Spn-810 for the Treatment of Impulsive Aggression in Adhd Patients, Spn-812 for the Treatment of Adhd and Spn-604 for the Treatment of Bipolar Disorder

from SC 13D/A ~10 pages Transactions During Past 60 Days

from SC 13D/A ~5 pages Transactions During Past 60 Days

from SC 13D ~20 pages Transactions During Past 60 Days

from S-1/A 40 pages [·] Shares Supernus Pharmaceuticals, Inc. Common Stock Underwriting Agreement

from S-1/A 34 pages Supernus Pharmaceuticals, Inc. [ ] Shares Common Stock ($0.001 Par Value) Underwriting Agreement